+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) - Drugs in Development, 2021

  • ID: 5315374
  • Report
  • April 2021
  • Region: Global
  • 30 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) - Drugs in Development, 2021

Summary

Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) - Drugs in Development, 2021 provides in depth analysis on Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report provides an overview of key players involved in Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products across relevant therapy areas under development targeting Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5).

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from the publisher' proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the Global therapeutic landscape for Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5).
  • The report reviews Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.
  • The report reviews key players involved in Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) targeted therapeutics and enlists all their major and minor projects.
  • The report assesses Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report summarizes all the dormant and discontinued pipeline projects.
  • The report reviews latest news and deals related to Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) targeted therapeutics.
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Identify and understand the targeted therapy areas and indications for Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5). Identify the use of drugs for target identification and drug repurposing.
  • Identify potential new clients or partners in the target demographic.
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it's most promising pipeline therapeutics.
  • Devise corrective measures for pipeline projects by understanding Large Neutral Amino Acids Transporter Small Subunit 1 (4F2 Light Chain or CD98 Light Chain or Integral Membrane Protein E16 or L Type Amino Acid Transporter 1 or Solute Carrier Family 7 Member 5 or y+ System Cationic Amino Acid Transporter or SLC7A5) development landscape.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown
  • Introduction
  • Report Coverage
  • Target - Overview
  • Target - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Target - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Target - Companies Involved in Therapeutics Development
  • Company 1
  • Company 2
  • Company 3
  • Company XX
  • Target - Drug Profiles
  • Drug Profile 1
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Drug Profile 2
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Drug Profile 3
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Drug Profile XX
  • Product Description
  • Mechanism of Action
  • R&D Progress
  • Target - Dormant Products
  • Target - Discontinued Products
  • Target - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indication, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by Company 1, 2021
  • Pipeline by Company 2, 2021
  • Pipeline by Company 3, 2021
  • Pipeline by Company XX, 2021
  • Dormant Products, 2021
  • Discontinued Products, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021
Note: Product cover images may vary from those shown
Adroll
adroll